drugset / Trial / NCT00637923

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

NCT00637923

Phase 2 Completed 112 enrolled Romark Laboratories L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.

Timeline

Start
2008-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 500 mg Oral
Background Peginterferon alfa-2a Protein / enzyme biologic 180 ug Other
Background Ribavirin Small molecule